Latest Immunomic Therapeutics Inc. Stories

2014-09-17 23:07:45

The $255,000 award will help ITI conduct vaccine validation studies over one year Hershey, PA & Rockville, MD (PRWEB) September 17, 2014 Immunomic Therapeutics, Inc. announced today that it won a Small Business Innovation Research (SBIR) grant to support the continued preclinical development of a multi-nut allergy immunotherapy. The award will provide ITI with approximately $255,000 over one year to conduct vaccine validation studies. Tree nuts, a leading cause of food allergy, affect...

2014-08-21 23:02:06

ITI moves one step closer to a solution for the worldwide allergy crisis. Hershey, PA & Rockville, MD (PRWEB) August 21, 2014 DNA vaccine pioneer Immunomic Therapeutics, Inc. (ITI) is making progress in its development of JRC-LAMP-vax, an innovative and safe potential treatment for allergy to Japanese red cedar pollen. Phase IC studies began this month in Hawaii, moving the world closer to a real solution to hay fever. The Japanese red cedar releases pollen that causes devastating...

2014-07-29 23:07:28

Dr. William Hearl to embark on a roadshow with Newport to showcase the company’s technology, progress to date, and future plans to the private and institutional investment community. Hershey, PA & Rockville, MD (PRWEB) July 29, 2014 July 29, 2014 - Immunomic Therapeutics, Inc. (ITI), a vaccine pioneer in the biotechnology industry, announced that it has engaged the financial services firm Newport Coast Securities, Inc. to explore financing opportunities that build shareholder...

2014-07-28 23:05:11

National Brain Tumor Society connects biotech company to researchers’ technology. Hershey, PA & Boston, MA (PRWEB) July 28, 2014 Immunomic Therapeutics, Inc. (ITI) has entered into collaboration agreements with two researchers to further develop potential treatments for glioblastoma multiforme (GBM), the most common and deadly malignant brain tumor, in combination with their patented vaccine platform, LAMP-vax. The agreements, recently executed by ITI and Duke University, are based...

2014-06-17 23:08:05

The milestone brings the company one step closer to an immunotherapy that could eradicate peanut allergy, one of the leading causes of death from food reactions. Hershey, PA & Rockville, MD (PRWEB) June 17, 2014 Vaccine leader Immunomic Therapeutics, Inc. (ITI) announced that it has successfully completed a model animal therapeutic and prophylactic study protocol for ARA-LAMP-vax, a breakthrough treatment that mitigates peanut allergy. The milestone brings the company one step closer...

2014-05-19 23:07:53

Dr. William Hearl will discuss the missing link in enhancing the effectiveness of DNA vaccines in a panel discussion on Wednesday, May 21 hosted by Ed Butler of the BBC Hershey, PA & Rockville, MD (PRWEB) May 19, 2014 Immunomic Therapeutics, Inc. (ITI), a vaccine pioneer in the biotechnology industry, is proud to announce that the company’s CEO, Dr. William G. Hearl, will be a featured panelist at the prestigious Future in Review (FiRe) Conference hosted by Strategic News Service...

Word of the Day
  • A cloth or covering, more or less ornamented, laid over the saddle or furniture of a horse, especially of a sumpter-horse or horse of state.
  • Clothing, especially sumptuous clothing; equipment; outfit.
  • To cover with a caparison, as a horse.
  • To dress sumptuously; adorn with rich dress.
This word ultimately comes from the Medieval Latin 'cappa,' cloak.